Oxford Biomedica plc
OXB.L · LSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | £128,797 | £89,539 | £139,989 | £142,797 |
| % Growth | 43.8% | -36% | -2% | – |
| Cost of Goods Sold | £75,776 | £49,812 | £70,808 | £60,157 |
| Gross Profit | £53,021 | £39,727 | £69,181 | £82,640 |
| % Margin | 41.2% | 44.4% | 49.4% | 57.9% |
| R&D Expenses | £4,544 | £59,353 | £60,937 | £40,189 |
| G&A Expenses | £29,420 | £25,413 | £28,223 | £15,152 |
| SG&A Expenses | £29,420 | £25,413 | £28,223 | £15,152 |
| Sales & Mktg Exp. | £0 | £0 | £0 | £0 |
| Other Operating Expenses | £58,432 | £139,135 | £31,579 | £6,366 |
| Operating Expenses | £92,396 | £223,901 | £120,739 | £61,707 |
| Operating Income | -£39,375 | -£184,174 | -£30,220 | £20,768 |
| % Margin | -30.6% | -205.7% | -21.6% | 14.5% |
| Other Income/Exp. Net | -£7,890 | -£4,353 | -£15,756 | -£888 |
| Pre-Tax Income | -£47,265 | -£188,527 | -£45,976 | £19,880 |
| Tax Expense | £1,344 | -£4,365 | -£817 | £869 |
| Net Income | -£43,190 | -£157,490 | -£39,157 | £19,011 |
| % Margin | -33.5% | -175.9% | -28% | 13.3% |
| EPS | -0.42 | -1.63 | -0.41 | 0.23 |
| % Growth | 74.2% | -297.6% | -278.3% | – |
| EPS Diluted | -0.42 | -1.63 | -0.41 | 0.22 |
| Weighted Avg Shares Out | 103,458 | 96,555 | 94,830 | 83,484 |
| Weighted Avg Shares Out Dil | 103,458 | 96,555 | 94,830 | 85,619 |
| Supplemental Information | – | – | – | – |
| Interest Income | £3,236 | £4,910 | £973 | £0 |
| Interest Expense | £9,839 | £11,199 | £8,754 | £888 |
| Depreciation & Amortization | £23,093 | £28,710 | £26,425 | £12,456 |
| EBITDA | -£14,333 | -£148,618 | -£10,797 | £33,224 |
| % Margin | -11.1% | -166% | -7.7% | 23.3% |